Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jackpot prize getting bigger.
Get cheaper! Fantastic! More $$$ inflow.
Patiently waiting. Coming SOON!!!
Did grabbed today. Averaging down.
Locked and holding!! GLTU
$HBRM
in a few days we will know how she blows. Deeply Watch her! LOL!
ASK 35!!! MM a friend!!!
PAUL is right there!!!
GRABBED them All!!!
TIME TO BUY BUY BUY BUY YYYYY
for over 5 months of loading/Q1 due in a matter of days
revenues will be huge!!! imo.
Grabbed. This is going to RUN hard...
Huge catalyst. Watching!
Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives
4/19/21, 5:00 AM
COLLEGE STATION, TX / ACCESSWIRE / April 19, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company").
We continue to make great strides in the application of our multiple platforms for production of therapeutics for treating infectious diseases. Our future success will follow as we meet our goals to bring these therapeutics to market with new developments made possible by our extensive platform for producing new and effective therapies.
We acknowledge our partners Genscript (https://www.genscript.com), STC Biologics (https://stcbiologics.com) and California National Primate Research Center (University of Southern California) for their continued support in our research and development efforts. We are also grateful for the overwhelming support from world-renowned scientists and continue to expand our team of advisors to build a strong company based on research and development.
We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon achievement of defined milestones. The milestones we have set include the following:
Monoclonal Antibodies for Treatment of HIV Milestones
1st Milestone: Testing of anti-HIV Monoclonal Antibodies at University of Montana
Status: in process. Time to completion: 1 month
2nd Milestone: Broad-based neutralization testing of existing anti-HIV Monoclonal Antibodies at University of Strasbourg, France
Status; in process. Time to completion: 2 months
3rd Milestone: Animal Studies of anti-HIV Monoclonal Antibodies at California National Primate Research Center, University of Southern California
Time to completion: 6 months following in vitro testing in process.
4th Milestone: Using Artificial Intelligence, identification of additional conserved immutable target sites (epitopes) on the HIV-1 virus
Status: Completed
5th Milestone: Production of additional Monoclonal Antibodies targeting identified sites (epitopes) on the HIV virus
Status: in process. Time to completion: 5-6 months
COVID-19
We are proud of the significant advances we have made in the development of Monoclonal Antibodies for treating Covid-19. We have reported that the Monoclonal Antibodies being produced by the Company will target immutable, conserved sites on SARS-CoV-2 (Coronavirus) that exist on the variant strains of the virus from the UK, Brazil, and South African.
These findings are considered highly significant in that the Center for Disease Control ("CDC") has reported these "variants of concern" are ones "for which there is evidence of an increase in transmissibility, more severe disease (meaning increased hospitalizations or deaths), a significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures."
Our AI platform developed in collaboration with Denver Scientific has been one of our many successes. The patentable discoveries will be significant in our ongoing partnering dialogue with pharmaceutical companies interested in treatments for the Coronavirus and numerous other infectious diseases.
We intent to expedite our development of anti-Coronavirus Monoclonal Antibodies including an eventual fast-track clinical trial to progress to market.
SARS-CoV-2 (Coronavirus) Monoclonal Antibodies Milestones
1st Milestone: Using Artificial Intelligence, identification of conserved immutable target sites (epitopes) on the Coronavirus
Status: Completed
2nd Milestone: Production of Monoclonal Antibodies targeting identified sites (epitopes) on the SARS-CoV-2 virus
Status: In process. Time to completion: 3-4 months
3rd Milestone: Fast-Track Clinical Studies
Time to Completion: 6 months following production of Monoclonal Antibodies
ITV-1 anti-HIV Therapeutics
Clinical trials are planned for the Company's patented anti-HIV therapeutics ITV-1. Earlier this year, we announced the execution of Articles of Association to form International Medical Partners ("IMPL"), a Bulgarian Limited Liability Company of which the Company is 50% owner. The Company's partners in IMBL will fund the total cost of the Clinical trials under the European Medicine Agency (the "EMA") standards and the application cost for the EMA permit for the Company's ITV-1 patented therapeutics for treating HIV. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company believes that issuance of the EMA permit for the ITV-1 compound could qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage a CRO to begin the clinical trials required under EMA standards.
We will have a definitive timeline for the expected date of initiation and completion of clinical trials in the coming weeks.
Production of Monoclonal Antibodies for HTLV-1/2
We are committed to developing "universal, durable and broadly neutralizing" Monoclonal Antibodies for many infectious diseases. We have an "intent to partner" agreement with a pharmaceutical company to create Monoclonal Antibodies against HTLV-1/2. We expect to complete the production by the end of 2021.
Monoclonal Antibodies for HTLV-1/2
1st Milestone: Using Artificial Intelligence, identification of conserved immutable target sites (epitopes) on the HTLV1/2 virus
Time to Completion: 2-3 months
2nd Milestone: Creation of anti-HTLV1/2 Monoclonal Antibodies
Time to completion: 6-8 months following identification of target epitopes
CEO Charles Cotropia said, "The strength of our company lies in our multiple technology platforms and the ability to produce fully human Monoclonal Antibodies against conserved and immutable targets on identified viruses. The viruses that may be addressed using our technology range from HIV to the Coronavirus to HTLV-1/2 to Ebola and many more. These numerous targeted viruses and bacteria are listed on our website [http://enzolytics.com/proprietary-therapeutics/]. We will continue to provide updates on our developments and progress toward completing the milestones we have set. We thank all our shareholders for their ongoing support of our Company and its technologies."
Q1 late iling April 20th grace period of 5 days from due date April 15th.
Great! Thanks.
Nice!
LOL! Agreed.
Anticipated Filing Date:
[Please note that the filing of this notification grants issuers 5 additional calendar days to post a Quarterly or Interim Report and 15 calendar days to post an Annual Report.]
We need a good Press Release of substance. Stop hints thru social media.
I do believe $ENZC. Not yet. I will buy at my time. Fast.
Too much shares up for sale.
To error is human! Misspellings happen! We apologize ; The news is still good - we are building our Asian team and strengthening the Singapore partnership to take advantage of the growing income of the markets; increase revenues and margins $HBRM https://t.co/TZXwBOfAh7
— Herborium (OTC: HBRM) (@Herborium1) April 13, 2021
New tweet! Screw HBRM. Hash hash...
Dude is on ignore. Not worth it.
True. The bulk is in Q1 2021 dah.
Q1 2021 ends Feb. they launched me mask feb 8th that means huge sales revenue
in one month!!!! Wow! Can’t wait to see Q1 financials.
Has been saying all along. Promising patience.
We will be rewarded.
$HBRM
Hmmm. A laughing stock for now.
Can’t wait to see a reversal from here.
I’ll add 16s to my diluted bag.
$HBRM
Yes sir. Peek a boo 19s. Will open !
I think we will be bullish tomorrow!
You all strong and patient will bank. Surely.
Sounds good ! Waiting on REVENUE growth update!
Promising patience.
Long & Strong
$HBRM
Reversal in play.
Zzzzzz
Damn. Great board here!
All I have to say is get your trade accounts liquid.
As soon this fly . Grab them. Never hesitate. Chase the bird
It’s worth it under $. .
Work with their agenda and will work for you too.
Yes. I’ll ignite the first million shares!
Great news! Promising patience! I’d like the 3s the 4s to show the least.
It would be nice if you get on board.
You DD is misguided this time. Ive known truly
your work has been right on with other tickets as a long.
You invest wisely as I followed you in the past.
GLTU
yes sir! She's trading nicely. Equilibium..longs holding strong.